JGC
IART icon

J. Goldman & Co’s Integra LifeSciences IART Stock Holding History

J. Goldman & Co’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,243,772
Closed -$15.4M – 761
2025
Q4 		$15.4M Buy
1,243,772
+292,961
+31% +$3.89M 0.41% 64
2025
Q3 		$13.6M Buy
950,811
+598,498
+170% +$8.2M 0.34% 89
2025
Q2 		$4.32M Buy
+352,313
New +$5.12M 0.1% 212
2025
Q1 		– Sell
-152,452
Closed -$3.46M – 544
2024
Q4 		$3.46M Sell
152,452
-102,826
-40% -$2.24M 0.09% 220
2024
Q3 		$4.64M Buy
+255,278
New +$5.92M 0.13% 171
2020
Q3 		– Sell
-11,039
Closed -$519K – 348
2020
Q2 		$519K Buy
+11,039
New +$543K 0.03% 215

Other funds holding IART

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

J. Goldman & Co's IART Position: Q1 2026 in Review

J. Goldman & Co sold out of Integra LifeSciences (IART) in Q1 2026, closing a stake of 1,243,772 shares — an estimated $15.4M sold.

J. Goldman & Co first reported a position in IART in Q2 2020 and held it in 6 quarters. The position peaked at $15.4M in Q4 2025. 202 funds tracked by Wall St. Rank hold IART as of Q1 2026.

  • J. Goldman & Co reported no remaining Integra LifeSciences position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 1,243,772 Integra LifeSciences shares in Q1 2026, an estimated $15.4M.
  • J. Goldman & Co first reported a position in Integra LifeSciences in Q2 2020 and held it in 6 quarters.
  • J. Goldman & Co's Integra LifeSciences position peaked at $15.4M in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.